Informations générales (source: ClinicalTrials.gov)
Impact of Closely Grouped, Iterative Exposures to Suxamethonium During Electroconvulsive Therapy (ECT) on the Sensitization to Neuro-Muscular Blocking Agents (NMBA) and the Development of Protective Antibodies
Observational
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
janvier 2022
septembre 2023
12 septembre 2025
Acute per-anesthetic hypersensitivity reaction (HSA-PA) is a rapidly occurring systemic
reaction following injection of a drug during anesthesia (mortality between 3 and 9%).
The substances responsible for these reactions in France are Neuro-Muscular Blocking
Agents (NMBA) in 60% of cases. The main mechanism mentioned is an immediate systemic
hypersensitivity immune reaction (anaphylaxis). The mechanism of immunization to NMBA is
not yet understood.
Electroconvulsive therapy (ECT) is a long-standing therapeutic approach still widely used
today, for its high efficiency, particularly in depressive syndromes resistant to
antidepressants. It has an efficacy comparable (or even superior) to pharmacological
treatments and improves the mortality associated with this disease. Treatment with
iterative ECT sessions includes an attack phase with an average of 12 sessions over 4
weeks, with secondary spacing of sessions before switching to antidepressant treatment.
These sessions are carried out in the operating room under general anesthesia, thanks to
a hypnotic and a NMBA, suxamethonium, as recently recommended by the French
Anesthesiology Society in 2020.
ECT therefore represent an interesting model of iterative exposure of a relatively
homogeneous population to a single highly sensitizing substance, which could make it
possible to study the evolution of sensitization as a function of various factors, in
particular cumulative exposure, for which no data is currently available.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| GHU PARIS PSY ET NEUROSCIENCES | GOUEL Aurélie | 01/11/2025 07:52:50 | Contacter | ||
| AP-HP Assistance publique - Hôpitaux de Paris | 01/11/2025 07:52:52 | Contacter | |||
| AP-HP - Hôpital Bicêtre | |||||
| AP-HP - Hôpital Bichat | |||||
| AP-HP - Hôpital La Pitié-Salpêtrière | |||||
| AP-HP - Hôpital Lariboisiere-Fernand Widal | |||||
| AP-HP - Hôpital Louis Mourier | |||||
| AP-HP - Hôpital Saint Antoine | |||||
Critères
Tous
Inclusion Criteria:
- Patient requiring iterative exposure to ECT as part of their psychiatric pathology
in one of the investigator center
- Patient who has not had ECT in the last 10 years for the phase E group, regardless
of their previous ECT exposure for the phase P group
- Patient who has been informed and has signed the consent form
- Patient requiring iterative exposure to ECT as part of their psychiatric pathology
in one of the investigator center
- Patient who has not had ECT in the last 10 years for the phase E group, regardless
of their previous ECT exposure for the phase P group
- Patient who has been informed and has signed the consent form
- Absence of written informed consent
- Allergies identified specifically to Neuro-Muscular Blocking Agents (NMBA)
- Patient under tutelage, curatorship or judicial protection
- Patient without social security
- Contraindication to ECT : intracranial hypertension, intracranial lesions without
intracranial hypertension, recent episode of cerebral hemorrhage, recent myocardial
infarction or embologenic disease, presence of aneurysms or vascular malformations
at risk of hemorrhage, retinal detachment, pheochromocytoma, history of ineffective
treatment with ECT having had serious side effects, taking anticoagulant treatments